Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01037231 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Oxabact Study
A Phase 2 study of Primary Hyperoxaluria, sponsored by OxThera.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT01037231: Completed Phase 2 study of Primary Hyperoxaluria, sponsored by OxThera.
NCT01037231 is a Phase 2 study of Primary Hyperoxaluria that has completed, run by OxThera. The registered enrollment target is 36 participants, below the 1,211-participant average among 3 other Primary Hyperoxaluria trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01037231, a Phase 2 study of Primary Hyperoxaluria, has completed, sponsored by OxThera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Oxalobacter formigenes
Study Locations (3)
Other
- University Children's Hospital (Division of Pediatric Nephrology) - Cologne
- Academy Medical Center, University of Amsterdam - Amsterdam
Minnesota
- Mayo Clinic (Department of Pediatric Nephrology) - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
What the finished NCT01037231 record still lists
NCT01037231 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,211-participant average among 3 other Primary Hyperoxaluria trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Primary Hyperoxaluria appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01037231 reports a single indexed study location in Other, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01037231 about?
NCT01037231 is a clinical study titled "Phase 2/3 Oxabact Study". The purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.
What is the current status of trial NCT01037231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2009-12. Estimated completion is 2011-01.
What conditions does trial NCT01037231 study?
This clinical trial studies the following conditions: Primary Hyperoxaluria.
What interventions are being tested in trial NCT01037231?
The interventions under investigation include: Placebo (DRUG), Oxalobacter formigenes (BIOLOGICAL).
Who is sponsoring clinical trial NCT01037231?
This trial is sponsored by OxThera, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01037231 being conducted?
This trial has 3 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperoxaluria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia